Ezetimibe

Papers on ezetimibe

294 papers104 new in 30 days

Thursday, November 19

Tuesday, November 17

Friday, November 13

Wednesday, November 11

Tuesday, November 10

Monday, November 9

AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Artery cross-sections contain plaque and contrasting sparse and dense cholesterol particles, surrounded by small upright, faceless people.
Cohort studyEvolocumab

Saturday, November 7

Circulation

Two cholesterol drugs showed no clear cardiovascular advantage

Over three years, cardiovascular events occurred in 8.5% of patients starting statin–ezetimibe therapy versus 7.9% starting a statin alone.Over three years, cardiovascular events occurred in 8.5% of patients starting statin–ezetimibe therapy versus 7.9% starting a statin alone.

Artery sections with similar fatty buildup sit side by side, with sparse cholesterol particles in the larger section and denser particles in the smaller.
Randomized trial · 3,048 peopleAtherosclerotic cardiovascular disease